British Journal of Ophthalmology · 2020 · 66 citations · 22 references
MedicineImmunologyOphthalmologyOcular DiseaseOcular ImagingOcular ImmunologyAutoimmune Eye DiseaseAutoimmune Ocular DiseaseOcular InflammationOrbital ImagingOrbital InflammationThyroid Eye DiseaseComparative Clinical ManifestationsExtraocular Muscle InflammationInflammatory Orbital Disease ImagingOrbital Fat CompartmentsOrbital Fat InflammationOrbital Imaging In InflammationPost-treatment Imaging AssessmentTeprotumumab Therapy
PURPOSE: Thyroid eye disease (TED) is a progressive, debilitating and potentially vision-threatening autoimmune disease. Teprotumumab, a novel human monoclonal antibody, has been shown to reverse the clinical manifestations of TED. Patients receiving teprotumumab have been shown in two multicenter, randomized placebo-controlled trials to have decreased proptosis, diplopia and inflammation after 24 weeks of treatment. This study aims to analyse volumetric and inflammatory changes on orbital imaging prior to and after teprotumumab treatment from one of these trials. DESIGN: Retrospective review. SUBJECTS: Six patients enrolled in the phase III teprotumumab clinical trial (OPTIC, NCT03298867) with active TED who received 24 weeks of teprotumumab and had pre- and post-treatment orbital imaging (CT or MRI). Additionally, 12 non-TED patients (24 orbits) were analysed as a comparative control group. METHODS: 3D volumetric calculations of the extraocular muscles (EOMs), orbital fat, and bony orbit were measured using previously validated image processing software. 3D volumetric results and changes in EOM inflammation were compared with clinical measurements of TED. RESULTS: Total EOM volume within each orbit was markedly reduced post-teprotumumab in all patients (n=six patients, 12/12 orbits, p<0.02). There was no statistical difference in post-treatment EOM volume when compared to non-TED controls. Total orbital fat volume was also reduced in 11 of 12 studied orbits (n=six patients, p=0.04). Overall EOM inflammation based on MRI signal intensity ratio was reduced in 8/8 orbits (n=four patients, p<0.01). CONCLUSION: Orbital imaging demonstrated decreased EOM volumes and orbital fat tissue volumes after teprotumumab treatment.
22
Teprotumumab for Thyroid-Associated Ophthalmopathy
Terry J. Smith, George J. Kahaly, Daniel G. Ezra et al. · New England Journal of Medicine · 2017 · 721 citations · Full text
Teprotumumab for the Treatment of Active Thyroid Eye Disease
Raymond S. Douglas, George J. Kahaly, Amy Patel et al. · New England Journal of Medicine · 2020 · 700 citations · Full text
Shanli Tsui, Neil Hoa, Catherine J. Hwang et al. · The Journal of Immunology · 2008 · 365 citations · Full text
Luigi Bartalena, G. E. Krassas, Wilmar M. Wiersinga et al. · The Journal of Clinical Endocrinology & Metabolism · 2012 · 363 citations · Full text